Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV002261881 | SCV002541031 | uncertain significance | not provided | 2021-04-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002488654 | SCV002781777 | uncertain significance | Upshaw-Schulman syndrome | 2022-02-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002261881 | SCV003266713 | uncertain significance | not provided | 2022-05-07 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 670 of the ADAMTS13 protein (p.Arg670His). This variant is present in population databases (rs149953167, gnomAD 0.03%). This missense change has been observed in individual(s) with ADAMTS13-related conditions (PMID: 23648131). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The histidine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV002261881 | SCV005330955 | uncertain significance | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | ADAMTS13: PM2, BP4 |